With the introduction of adaptive deep brain stimulation (aDBS) for Parkinson's disease, new questions emerge regarding who, why, and how to treat. This paper outlines the pathophysiological rationale ...
A groundbreaking international clinical trial has been testing an implanted adaptive deep brain stimulation (aDBS) device as a treatment therapy for Parkinson’s.
Through Nexalin America, the Company’s division dedicated to U.S. government engagement, the Company participated in advocacy efforts supporting the inclusion of language favorable to deep brain ...
The findings, to be published online Dec. 10 in eLife, hold direct implications for an increasingly widespread therapeutic approach called deep-brain stimulation. They point to DBS's potential for ...
Patent Approval Reinforces Nexalin’s Leadership in Non-Invasive Brain Stimulation for Addiction Treatment HOUSTON, TX, April 14, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) ...
There is still no cure for Parkinson’s disease, but the U.S. Food and Drug Administration (FDA) approved a new deep brain stimulator that could benefit patients with the motor condition. On Feb 24, ...
Mayo Clinic researchers have found a new way to more precisely detect and monitor brain cell activity during deep brain stimulation, a common treatment for movement disorders such as Parkinson's ...
Deep brain stimulation may provide immediate improvement in arm and hand strength and function weakened by traumatic brain injury or stroke. Deep brain stimulation may provide immediate improvement in ...
The Times of Israel on MSN
In breakthrough, Israeli scientists use deep-brain stimulation to counter schizophrenia
Novel study by researchers at the Rambam Health Care Campus could help 21 million people worldwide suffering from the severe ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results